hrp0094p1-55 | Bone B | ESPE2021
, Nilsson Ola
Retinoic acid receptor agonists can have dramatic negative effects on growth and even induce premature growth cessation and epiphyseal fusion (1, 2). An 11 5/12-year-old, prepubertal girl with fibrodysplasia ossificans progressiva presented in our pediatric skeletal disorders clinic with the concern of early growth cessation. She had participated in a clinical trial of Palovarotene (MOVE, NCT03312634), a retinoic acid receptor-gamma agonist, since the age of 9 10/1...